151
Participants
Start Date
May 28, 2020
Primary Completion Date
June 5, 2025
Study Completion Date
July 9, 2025
Domvanalimab
Domvanalimab is a humanized monoclonal antibody targeting human TIGIT
Etrumadenant
Etrumadenant is an A2aR and A2bR antagonist
Zimberelimab
Zimberelimab is a fully human anti-PD-1 monoclonal antibody
Clinical Research Alliance, Lake Success
Northwell Health Cancer Institute, Lake Success
Allegheny General Hospital (AGH)-Alleghney Singer Research Institute, Pittsburgh
Virginia Cancer Specialists, Fairfax
Oncology and Hematology Associates of Southwest Virginia, Inc., DBA Blue Ridge Cancer Care, Blacksburg
Wake Forest Baptist Health, Winston-Salem
Florida Cancer Specialists - Panhandle, Tallahassee
Florida Cancer Specialists, Gainesville
Florida Cancer Specialists - East, West Palm Beach
Florida Cancer Specialists, Englewood
University of Alabama at Birmingham, Birmingham
Sarah Cannon Research Institute, Nashville
Norton Cancer Institute, Louisville
Baptist Health Lexington, Lexington
Ochsner Clinic Foundation, New Orleans
The Center For Cancer And Blood Disorders (Texas Cancer Care), Fort Worth
Millennium Oncology, Houston
Innovative Clinical Research Institute (ICRI), Whittier
The Valley Hospital - Valley Health System - The Robert and Audrey Luckow Pavilion, Ridgewood
Border Medical Oncology, Albury
Coffs Harbour Health Campus, Coffs Harbour
Adelaide Cancer Centre, Elizabeth Vale
Shoalhaven Cancer Care Centre, Nowra
McGill University Health Centre (MUHC) - The Montreal Children's Hospital (MCH), Montreal
Hong Kong United Oncology Centre, Hong Kong
Queen Elizabeth Hospital (Hong Kong), Hong Kong
Curie Oncology, Singapore
Kosin University Gospel Hospital, Busan
Chungbuk National University Hospital (CBNUH), Cheongju-si
Chonnam University Hospital, Hwasun
Gachon University Gil Medical Center, Incheon
Chonbuk National University Hospital, Jeonju
Seoul National University Bundang Hospital, Seongnam-si
Asan Medical Center, Seoul
Kangbuk Samsung Hospital, Seoul
Korea University Anam Hospital, Seoul
St Vincent Hospital of the Catholic University of Korea, Suwon
Catholic University of Korea, Uijeongbu St. Mary's Hospital, Uijeongbu-si
Taipei Medical University - Shuang Ho Hospital, New Taipei City
Chi Mei Hospital, Tainan City
National Cheng Kung University Hospital, Tainan City
National Taiwan University Hospital, Taipei
Taipei Medical University Hospital, Taipei
Chang Gung Memorial Hospital at Linkou, Taoyuan District
Lead Sponsor
Collaborators (1)
Gilead Sciences
INDUSTRY
Arcus Biosciences, Inc.
INDUSTRY